Fulcrum Therapeutics is reinventing itself around migraine, agreeing to combine with privately held Slate Medicines in a reverse merger that hands most of the new company to Slate’s backers.
Fulcrum becomes a subsidiary of Slate; the combined company keeps the Slate name and trades on Nasdaq as SLTE.
What a reverse merger is, and why it happens
In a reverse merger a private company combines with a public one and effectively takes it over — the private company’s management, assets and identity continue while the public company’s listing is inherited.
The attraction is the listing itself. Going public conventionally requires an IPO: months of preparation, regulatory filings, banker fees and a market willing to buy. A reverse merger delivers the listing directly, and in biotech it has become the standard route for a private company to go public when the IPO window is unfavourable — or when a failed public company’s shell and cash are available cheaply.
The 5% figure tells the story
Fulcrum’s investors will hold just 5% of the combined company; Slate’s will hold 95%.
That split is the clearest possible statement of relative value. Fulcrum held about $333 million in cash at the end of Q1 2026 — a substantial sum — and its shareholders are receiving a twentieth of the merged entity.
The reconciliation is that Fulcrum will pay shareholders a cash dividend for net cash above a set threshold. So they are getting cash out plus a small equity stake, rather than exchanging their cash for a proportionate share.
The implicit valuation of Fulcrum’s remaining pipeline, after that cash is stripped out, is close to nothing.
Why Fulcrum needed this
The company pivoted after discontinuing its sickle cell drug pociredir when the FDA flagged a risk of secondary blood cancers — echoing safety issues that led to the withdrawal of a similar drug earlier in 2026.
That is a difficult category of failure. A drug that simply does not work leaves a company with a platform and a next candidate. A drug discontinued over a cancer risk that also affected a similar agent raises questions about the mechanism, not just the molecule — which devalues everything built on it.
A company in that position with substantial cash and a discredited approach is precisely the shell a private company wants.
What Slate is building
The combined company will focus on next-generation migraine therapeutics aimed beyond CGRP-targeting drugs.
The lead programme, SLTE-1009, is a PACAP inhibitor — targeting a different biological pathway than CGRP — licensed from a Chinese drugmaker and designed for patients who do not respond to approved therapies. It is expected to enter Phase 1 soon, alongside a second antibody programme.
Why PACAP is a credible second target
CGRP-targeting drugs transformed migraine treatment, and they do not work for everyone — a substantial minority of patients respond inadequately or not at all, and they currently have nowhere to go.
PACAP is a neuropeptide with a genuinely strong claim to being the next target. Infusing it into people triggers migraine attacks in those susceptible, which is close to direct human evidence of causal involvement — the same kind of provocation evidence that supported CGRP before drugs against it existed.
Critically, PACAP appears to act through a partly independent pathway, so blocking it could work in patients CGRP inhibitors fail. That is the specific commercial thesis: not competing with CGRP drugs, but serving the population they leave behind.
The money
Slate raised $130 million initially and announced an additional $245 million financing — substantial funding for a company entering Phase 1.
That scale of backing before human data indicates investors are treating PACAP as a validated target where execution rather than biology is the risk. It also reflects how large the migraine market has proven: CGRP drugs demonstrated that patients and payers will support expensive preventive therapy, which de-risks the commercial question for a follow-on mechanism.
The pattern
Slate CEO Gregory Oakes will lead the merged company, which expects to close by year-end 2026.
What CGRP proved about the migraine market
The financing behind Slate makes more sense against what the CGRP class demonstrated commercially, which was not obvious beforehand.
Migraine had long been treated as a condition managed with cheap generics — repurposed blood pressure and epilepsy drugs for prevention, triptans for attacks. The prevailing assumption was that payers would resist expensive branded therapy for a condition that was disabling but not life-threatening, and that patients would tolerate the older drugs.
CGRP therapies disproved both. Uptake was substantial despite high prices and step-therapy requirements, because the drugs were genuinely better tolerated and patients who had abandoned prevention returned to it.
That established migraine as a market capable of supporting premium pricing, which is the precondition for investing several hundred million dollars in a follow-on mechanism. A company targeting the patients CGRP drugs fail is not gambling on whether the market exists — only on whether PACAP blockade works.
The transaction is a tidy example of how biotech recycles. A failed company’s cash and listing are redeployed behind a different scientific bet, its shareholders are partially cashed out, and the capital continues working. Efficient, and unsentimental about what it means for the people who backed the original thesis. Business news, not investment advice.